Hey Edmo. As far as I can tell - it's just giving a breakdown of the randomised part of the SOLVE study. 99 participants, 52 in the control, 47 in the treatment. all patients were high-risk and previously untreatable for lead therapy. This in itself is really important as the FDA really want randomised studies in the overall package when assessing for approval.
but I guess we'll get a full update of the results - comparing control and treatment groups - before open of the ASX tomorrow.
Clearly EBR is excited about the results though.
General Investor Information EBR Systems, page-180
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.000(0.00%) |
Mkt cap ! $321.9M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.08 | $1.03 | $145.3K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 3403 | 2 |
View Market Depth
| Last trade - 15.59pm 08/08/2024 (20 minute delay) ? |
| EBR (ASX) Chart |